On December 18, 2024, the "High-Quality Development Forum" was hosted by the Institute of Advanced Clinical Medicine at Peking University (IACM). During the event, Baheal's invested enterprise, CAIUSLY Technology Co., Ltd. (CAIUSLY), signed an agreement with IACM to co-establish the "Organ-on-a-Chip and 3D Disease Modeling Joint Laboratory".

The signing ceremony was attended by several distinguished guests. Among them were Han Qide, Vice Chairman of the 12th National Committee of the Chinese People's Political Consultative Conference, Honorary President of the China Association for Science and Technology, and Academician of the Chinese Academy of Sciences; Qiao Jie, Executive Vice President of Peking University, Director of the Peking University Health Science Center, and Academician of the Chinese Academy of Engineering; Wang Cenyu, Dean of the Institute of Advanced Clinical Medicine at Peking University and Foreign Academician of the Chinese Academy of Engineering; Dong Erdan, Director of the Cardiovascular Research Institute at Peking University, Director of the National Key Laboratory of Vascular Homeostasis and Remodeling, and Academician of the Chinese Academy of Engineering; Xiao Yuan and Wang Jiadong, both Deputy Directors of the Peking University Health Science Center, Fu Gang, Chairman of Baheal Pharma Group, Li Lihua, Vice President of Research Management at Baheal, Zhang Qijun, Chairman of CAIUSLY, and Wang Tao, Chief Scientist of CAIUSLY.

Organ-on-chip technology, a cutting-edge in vitro research method, enables the construction and simulation of different human tissues and organ functions outside the human body. This approach is used to study organ functions, biological targets, and the effects and toxicity of drugs, overcoming limitations like species differences that usually will appear in animal testing. CAIUSLY, a platform invested and incubated by Baheal, focuses on multi-organ-on-a-chip micro-physiological system. By integrating advanced technologies such as microfluidics, stem cell differentiation, and gene editing, CAIUSLY has created human multi-organ micro-physiological systems that provide a more comprehensive simulation of human physiology compared to single organ chips. This innovation improves the reliability of research data and the efficiency of the R&D process. It has significant potential applications in disease research, new drugs discovery and testing, and personalized treatment.

Drawing on the clinical medical resources and technical capabilities advantages of the Institute of Advanced Clinical Medicine (IACM) and CAIUSLY, the Joint Laboratory will focus on several key areas: developing biomimetic microfluidic and control systems, creating 3D micro-organ disease models, researching biological targets and targeted therapies, and monitoring new drug efficacy and toxicity. This partnership aims to create a highly efficient and innovation transformation model that seamlessly integrates basic research, clinical studies, and industrial applications. The goal is to accelerate the R&D of innovative pharmaceutical products to meet the increasing demand for precision medicine and personalized healthcare in the future.

The establishment of this Joint Laboratory signifies a deeper strategic partnership between Baheal Pharma Group and Peking University Health Science Center. Baheal has previously built a strong foundation of scientific collaboration with Peking University Health Science Center in areas such as nuclear medical molecular imaging, atherosclerosis, and targeted integrin small molecule inhibitors. Moreover, Baheal has supported Peking University Health Science Center’s research and innovation by donating funds for achievement transformation and education, thereby aiding talent development and institutional growth.

At the forum, the Institute of Advanced Clinical Medicine at Peking University awarded certificates of appreciation to Baheal Pharma Group, CAIUSLY, and other partners in recognition of their valuable contributions and collaboration.